Business Context and Reporting Period
Company: Passage BIO, Inc. (Nasdaq: PASG)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Passage BIO is a clinical-stage genetic medicines company focused on developing one-time gene therapies for neurodegenerative diseases. Its lead product candidate, PBFT02, is a gene replacement therapy targeting progranulin deficiency in Frontotemporal Dementia (FTD-GRN). The company also has preclinical programs for Huntington's disease and is exploring PBFT02 for FTD-C9orf72, ALS, and Alzheimer's disease.
Key Financial Metrics
| Metric | 2025 (in millions) | 2024 (in millions) |
|---|---|---|
| Net Loss | $(45.5) | $(64.8) |
| Research & Development Expenses | $23.3 | $40.2 |
| General & Administrative Expenses | $19.9 | $25.0 |
| Impairment of Long-Lived Assets | $6.1 | $5.2 |
| Cash and Cash Equivalents (Year End) | $46.3 | $37.6 |
| Accumulated Deficit | $(704.8) | $(659.2) |
| Net Cash Used in Operating Activities | $(31.5) | $(48.0) |
Note: The company has no revenue from product sales. The filing text does not provide specific gross margin or operating margin data as the company is pre-commercial.
Material Changes vs. Prior Period
- Expense Reduction: Net loss decreased by approximately 30% year-over-year, driven primarily by a $16.9 million reduction in R&D expenses and a $5.1 million reduction in G&A expenses. This was achieved through a 55% workforce reduction announced in January 2025 and the cessation of laboratory operations in Hopewell, New Jersey.
- Asset Impairment: The company recorded $6.1 million in impairment charges in 2025 (up from $5.2 million in 2024) related to the Hopewell laboratory space and equipment following the decision to cease lab operations.
- Portfolio Restructuring: The company outlicensed three pediatric programs (GM1, Krabbe, and MLD) to Gemma Biotherapeutics, Inc. in 2024/2025. As of December 31, 2025, the company had collected $7.5 million in initial payments and $4.8 million in transition services payments, recorded as liabilities pending revenue recognition criteria.
- Capital Structure: A 1-for-20 reverse stock split was effected on July 14, 2025, to regain compliance with Nasdaq listing requirements.
Guidance, Outlook, and Risks
Outlook and Guidance
- Cash Runway: Management expects existing cash and cash equivalents ($46.3 million) to fund operating expenses and capital expenditures through the end of the first quarter of 2027.
- Clinical Milestones: The company expects to report updated interim safety and biomarker data from the upliFT-D trial (PBFT02) in the first half of 2026. It also plans to seek regulatory feedback on registrational trial design for FTD-GRN in the first half of 2026.
- Manufacturing: The company has aligned with the FDA on an analytical plan to establish comparability between its current clinical product and a new high-productivity, suspension-based manufacturing process.
Risks and Contingencies
- Liquidity Risk: The company has a history of operating losses and will require substantial additional capital to continue operations. Failure to raise capital could force delays or termination of development programs.
- Clinical Development Risk: PBFT02 is the sole clinical-stage product candidate. While biomarker data (CSF PGRN levels) has been positive, serious adverse events (venous sinus thrombosis, hepatotoxicity) occurred at Dose 1, leading to protocol amendments including prophylactic anticoagulation.
- Legal Proceedings: The company is defending an appeal by a former employee regarding a settlement agreement from 2020. While the Superior Court of Pennsylvania affirmed judgment in the company's favor in September 2025, the plaintiff petitioned the Pennsylvania Supreme Court in December 2025, which is currently pending.
- Regulatory Risk: As a clinical-stage biotech, the company faces significant uncertainty regarding FDA approval timelines and requirements for novel gene therapies.
Key Facts for Investor Verification
- Cash Position: Verify the $46.3 million cash balance and the specific assumptions used to project a runway through Q1 2027.
- Revenue Recognition: Confirm the accounting treatment of the $12.3 million collected from Gemma Biotherapeutics (recorded as a liability, not revenue, due to collectability/obligation criteria).
- Clinical Safety: Monitor upcoming data releases in H1 2026 regarding the safety profile of Dose 2 and the efficacy of the prophylactic anticoagulation protocol.
- Legal Status: Track the status of the pending Pennsylvania Supreme Court review regarding the former employee litigation.
- Manufacturing Transition: Verify the timeline for transitioning from the current adherent-based manufacturing process to the new suspension-based process to support future clinical and commercial needs.